AXSM Key Statistics, Chart & Performance
The current stock price of AXSM is 149.735 USD. In the past month the price increased by 13.78%. In the past year, price increased by 54.25%.
AXSM Latest News, Press Relases and Analysis
AXSM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.58 | 1.01T | ||
| JNJ | JOHNSON & JOHNSON | 19.89 | 497.38B | ||
| MRK | MERCK & CO. INC. | 11.74 | 256.74B | ||
| PFE | PFIZER INC | 8.04 | 146.26B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.47 | 99.80B | ||
| ZTS | ZOETIS INC | 20.26 | 56.59B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.69 | 22.99B | ||
| VTRS | VIATRIS INC | 4.58 | 12.30B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.1 | 11.50B | ||
| CORT | CORCEPT THERAPEUTICS INC | 89.08 | 8.25B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.36B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.25B |
Related stock screener links
About AXSM
Company Profile
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. The company is headquartered in New York City, New York and currently employs 683 full-time employees. The company went IPO on 2015-11-19. The firm is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The firm's commercial products include Auvelity, Sunosi and Symbravo. The company is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, Solriamfetol, AXS-12 and AXS-14. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.
Company Info
AXSOME THERAPEUTICS INC
One World Trade Center, 29Th Floor
New York City NEW YORK 10038 US
CEO: Herriot Tabuteau
Employees: 683
Phone: 12123323241
AXSOME THERAPEUTICS INC / AXSM FAQ
What does AXSM do?
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. The company is headquartered in New York City, New York and currently employs 683 full-time employees. The company went IPO on 2015-11-19. The firm is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The firm's commercial products include Auvelity, Sunosi and Symbravo. The company is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, Solriamfetol, AXS-12 and AXS-14. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.
What is the stock price of AXSOME THERAPEUTICS INC today?
The current stock price of AXSM is 149.735 USD. The price decreased by -1.17% in the last trading session.
Does AXSOME THERAPEUTICS INC pay dividends?
AXSM does not pay a dividend.
What is the ChartMill rating of AXSOME THERAPEUTICS INC stock?
AXSM has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does AXSOME THERAPEUTICS INC belong to?
AXSOME THERAPEUTICS INC (AXSM) operates in the Health Care sector and the Pharmaceuticals industry.
What is the market capitalization of AXSM stock?
AXSOME THERAPEUTICS INC (AXSM) has a market capitalization of 7.55B USD. This makes AXSM a Mid Cap stock.
What is the outstanding short interest for AXSOME THERAPEUTICS INC?
The outstanding short interest for AXSOME THERAPEUTICS INC (AXSM) is 8.72% of its float.
AXSM Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to AXSM. When comparing the yearly performance of all stocks, AXSM is one of the better performing stocks in the market, outperforming 91.35% of all stocks.
AXSM Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AXSM. AXSM may be in some trouble as it scores bad on both profitability and health.
AXSM Financial Highlights
Over the last trailing twelve months AXSM reported a non-GAAP Earnings per Share(EPS) of -4.67. The EPS increased by 28.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.3% | ||
| ROE | -311.32% | ||
| Debt/Equity | 2.61 |
AXSM Forecast & Estimates
26 analysts have analysed AXSM and the average price target is 182.31 USD. This implies a price increase of 21.76% is expected in the next year compared to the current price of 149.735.
For the next year, analysts expect an EPS growth of 38.6% and a revenue growth 60.86% for AXSM